Home » Stocks » TRIL

Trillium Therapeutics Inc. (TRIL)

Stock Price: $9.11 USD -0.15 (-1.62%)
Updated May 11, 2021 4:00 PM EDT - Market closed
After-hours: $9.05 -0.06 (-0.66%) May 11, 7:30 PM
Market Cap 938.69M
Revenue (ttm) 116,078
Net Income (ttm) -109,020
Shares Out 103.14M
EPS (ttm) -0.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 11
Last Price $9.11
Previous Close $9.26
Change ($) -0.15
Change (%) -1.62%
Day's Open 9.06
Day's Range 8.95 - 9.42
Day's Volume 1,031,181
52-Week Range 5.31 - 20.96

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Trillium Therapeutics Inc (NASDAQ: TRIL) has provided a data update for TTI-622 and 621 programs in hematologic malignancies. As of cut-off data April 12, TTI-622 monotherapy shows a 33% objective respo...

1 week ago - Benzinga

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, ...

1 week ago - GlobeNewsWire

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, ...

1 week ago - GlobeNewsWire

Their stocks have collapsed. But they could still be huge winners.

Other stocks mentioned: AXSM, FREQ
1 week ago - The Motley Fool

Though these stocks have dropped, upcoming news offers hope for them to rebound.

Other stocks mentioned: BLUE, SAGE
1 month ago - The Motley Fool

CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, ...

1 month ago - GlobeNewsWire

Infinity Pharmaceuticals is my pick for Stock of the Year. And Shopify is my selection for Stock of the Decade.

Other stocks mentioned: AMZN, BMY, GILD, INFI, NVAX, RHHBY, SHOP ...
2 months ago - The Motley Fool

The cancer biotech soared in 2020, jumping up over 1,000% for the year. What will the stock do in 2021?

3 months ago - The Motley Fool

Trillium Therapeutics has two lead candidates that encourage immune cells known as “macrophages” to gobble up cancer cells by blocking a protein known as CD47. However, the CD47 inhibitor space is incre...

3 months ago - Seeking Alpha

Buy these three biotech stocks before they take off.

Other stocks mentioned: AMGN, ILMN
3 months ago - The Motley Fool

When it comes to countering a key trick that cancer plays on the human immune system, this biotech has no equal.

3 months ago - The Motley Fool

Biotech, bitcoin, and renewable energy led the way.

Other stocks mentioned: BEEM, BLNK, BTBT, CRDF, MARA, NIO, NVAX ...
4 months ago - The Motley Fool

The company's long-term plan is to challenge conventional cancer therapy.

4 months ago - The Motley Fool

This clinical-stage biotech stock could be a top buyout candidate in 2021.

4 months ago - The Motley Fool

Find out what these healthcare businesses can do to deliver big gains this year.

Other stocks mentioned: NNOX, TDOC
4 months ago - The Motley Fool

The biopharma sector weathered the COVID-19 pandemic fairly well, with the Shares Nasdaq Biotechnology Etf (NASDAQ: IBB) outperforming the S&P 500 Index. This defensive sector also benefited from opport...

Other stocks mentioned: CRDF, GNPX, NVAX, VXRT
4 months ago - Benzinga

Investors need to pay close attention to Trillium (TRIL) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

A decline in the stock price plus positive clinical data equals opportunity.

4 months ago - The Motley Fool

The highest performers of the year are biotechs fighting COVID-19 and cancer. Are they still buys for 2021?

Other stocks mentioned: BNTX, CLDX, CODX, CRDF, MCRB, MRNA, NSRGY ...
4 months ago - The Motley Fool

Trillium Therapeutics (TRIL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

5 months ago - Zacks Investment Research

The micro-cap has shot up an incredible 1,400% this year.

5 months ago - The Motley Fool

A new CEO and prioritization of research could have more big gains in store for the company

5 months ago - The Motley Fool

CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ( “ Trillium ” or the “ Company ” ) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative ther...

5 months ago - GlobeNewsWire

Biotech investors had more than just vaccines to think about this year.

Other stocks mentioned: CRDF, FPRX, MRSN, SURF
5 months ago - The Motley Fool

Investors are catching on to the opportunity for this innovative cancer therapy, and so is big pharma.

5 months ago - The Motley Fool

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, t...

5 months ago - GlobeNewsWire

CAMBRIDGE, Ma., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies fo...

5 months ago - GlobeNewsWire

Trillium Therapeutics has an encouraging pipeline with key differentiators that have attracted recent investor interest. The 2 major candidates, TTI-621 & 622 have shown monotherapy activity in a breadt...

5 months ago - Seeking Alpha

Industry Veteran Brings Deep Executive and Commercial Experience to Trillium Board Industry Veteran Brings Deep Executive and Commercial Experience to Trillium Board

5 months ago - GlobeNewsWire

Adaptimmune Therapeutics and Trillium Therapeutics could be big winners for early shareholders.

Other stocks mentioned: ADAP
6 months ago - The Motley Fool

CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ( “ Trillium ” or the “ Company ” ) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative ther...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies ...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies ...

7 months ago - GlobeNewsWire

Investors need to pay close attention to Trillium (TRIL) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

Industry Veteran Brings Deep Biologics Manufacturing Experience to Trillium Board Industry Veteran Brings Deep Biologics Manufacturing Experience to Trillium Board

7 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapi...

7 months ago - GlobeNewsWire

Trillium (TRIL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

Sorrento Therapeutics and Trillium Therapeutics could both be poised for another explosive move higher.

Other stocks mentioned: SRNE
7 months ago - The Motley Fool

CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapi...

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapi...

8 months ago - GlobeNewsWire

Shares of clinical stage immuno-oncology company Trillium Therapeutics Inc's (NASDAQ: TRIL) are trading higher on encouraging updated data from its ongoing lead cancer candidates TTI-622 and TTI-621 tha...

Other stocks mentioned: PFE
8 months ago - Benzinga

Trillium lands a noteworthy equity stake from pharma titan Pfizer.

8 months ago - The Motley Fool

CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapi...

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapi...

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapie...

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies...

9 months ago - GlobeNewsWire

Investors need to pay close attention to Trillium Therapeutics (TRIL) stock based on the movements in the options market lately.

9 months ago - Zacks Investment Research

CAMBRIDGE, Mass., July 06, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) (the “Corporation”), a clinical stage immuno-oncology company developing innovative therapies for the ...

10 months ago - GlobeNewsWire

These are the biotech stocks with the best value, fastest growth, and most momentum for Q3 2020.

Other stocks mentioned: GMAB, IBB, INVA, NVAX, VNDA, VRTX, XBIT
11 months ago - Investopedia

Trillium Therapeutics (NASDAQ: TRIL) shares are trading higher on Friday, after the company provided an update on TTI-622 at ASCO.

11 months ago - Benzinga

About TRIL

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company ... [Read more...]

Industry
Biotechnology
Founded
2004
Stock Exchange
NASDAQ
Ticker Symbol
TRIL
Full Company Profile

Financial Performance

In 2020, TRIL's revenue was 148,000, an increase of 19.35% compared to the previous year's 124,000. Losses were -59.35 million, 55.8% more than in 2019.

Financial numbers in millions CAD.
Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for TRIL stock is "Strong Buy." The 12-month stock price forecast is 11.02, which is an increase of 20.97% from the latest price.

Price Target
$11.02
(20.97% upside)
Analyst Consensus: Strong Buy